Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

13.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
13.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimization of Subsecond Estradiol Detection through Analysis of Surface-Analyte Interactions.

ACS electrochemistry·2026
Same author

The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.

The oncologist·2026
Same author

Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Prospective Multisite Validation and Comparison with MRI.

The Journal of urology·2026
Same author

Guanosine contributes to rapid purinergic regulation of dopamine during ischemia.

Purinergic signalling·2026
Same author

Comparative Performance of Prostate Cancer Risk Prediction Tools in Gay, Bisexual, and Other Men Who Have Sex With Men vs Heterosexual Men.

Urology·2026
Same author

Clinical and Reader Associated Correlates of Clinically Significant Magnetic Resonance Imaging-Invisible Prostate Cancer Based on Negative Scans.

The Journal of urology·2026
Same journal

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

European urology oncology·2026
Same journal

Overall Survival Benefit from Metformin in High-volume Metastatic Hormone-sensitive Prostate Cancer in STAMPEDE Signals an Opportunity for Metabolically-targeted Therapies in Prostate Cancer.

European urology oncology·2026
Same journal

Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT.

European urology oncology·2026
Same journal

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.

European urology oncology·2026
Same journal

PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients?

European urology oncology·2026
Same journal

Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry.

European urology oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting.

Michael S Leapman1, Julian Ho2, Yang Liu2

  • 1Department of Urology, Yale School of Medicine, New Haven, CT, USA; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.

European Urology Oncology
|August 4, 2024
PubMed
Summary
This summary is machine-generated.

The Decipher genomic classifier (GC) accurately predicts metastasis and recurrence risk in prostate cancer patients in real-world settings. This study validates its prognostic significance in contemporary clinical practice.

Keywords:
Biochemical recurrenceDecipherLinkageMetastasisOutcomesPrognosisProstate biopsyProstate cancerProstatectomyReal-world dataTranscriptome

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

638
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K

Related Experiment Videos

Last Updated: Jun 18, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

638
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K

Area of Science:

  • Genomic Medicine
  • Oncology
  • Prostate Cancer Research

Background:

  • Prognostic significance of Decipher prostate cancer genomic classifier (GC) is mainly from archival tissue.
  • Limited data exists on Decipher GC associations with outcomes in real-world, contemporaneous settings.

Purpose of the Study:

  • Assess Decipher GC associations with metastasis and biochemical recurrence (BCR) risks.
  • Evaluate outcomes in patients receiving real-world testing and treatment.

Main Methods:

  • Retrospective cohort study linking Decipher GC transcriptomic data with real-world clinical data (RWD).
  • Analysis of insurance claims, pharmacy records, and EHR data.
  • Kaplan-Meier and Cox proportional hazards regressions used for outcome analysis.

Main Results:

  • Over 58,935 participants underwent Decipher testing (biopsy and RP specimens).
  • Decipher GC independently associated with metastasis risk in biopsy-tested (HR 1.21) and RP-tested (HR 1.20) patients.
  • Decipher GC associated with BCR risk in RP-tested patients (HR 1.12).

Conclusions:

  • Real-world, national-scale study supports external prognostic validity of Decipher GC.
  • Findings validate Decipher GC use in contemporary prostate cancer management.
  • Genomic classifier aids in estimating prostate cancer recurrence and metastasis risk.